New trends in the treatment of bone metastasis

被引：17

作者：

Keller, Evan T. ^{[1
]}

Dai, Jinlu ^{[1
]}

Escara-Wilke, June ^{[1
]}

Hall, Christopher L. ^{[1
]}

Ignatoski, Kathleen ^{[1
]}

Taichman, Russell S. ^{[1
]}

Keller, Jill ^{[1
]}

机构：

[1] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA

来源：

JOURNAL OF CELLULAR BIOCHEMISTRY | 2007年 / 102卷 / 05期

关键词：

prostate cancer; breast cancer; SDF; CXCR4; BMP; Wnt; RANKL; PTHrP;

D O I：

10.1002/jcb.21540

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Bone metastasis is often the penultimate harbinger of death for many cancer patients. Bone metastases are often associated with fractures and severe pain resulting in decreased quality of life. Accordingly, effective therapies to inhibit the development or progression of bone metastases will have important clinical benefits. To achieve this goal understanding the mechanisms through which bone metastases develop and progress may provide targets to inhibit the metastases. In the past few years, there have been advances in both understanding the mechanisms through which bone metastases develop and how they impact bone remodeling. Additionally, gains in promising clinical strategies to target bone metastases have been developed. In this prospectus, we will discuss some of these advances.

引用

页码：1095 / 1102

页数：8

共 93 条

[1]

Akashi T, 2006, ONCOL REP, V16, P831

[2] In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates [J].